Verition Fund Management’s SpringWorks Therapeutics SWTX Stock Holding History

Verition Fund Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-313,408	Closed	-$14.7M	–	3990
2025 Q2	$14.7M	Buy	313,408 +154,624	+97%	+$6.88M	0.07%	341
2025 Q1	$7.01M	Buy	+158,784	New	+$7.31M	0.03%	631
2024 Q4	–	Sell	-17,500	Closed	-$561K	–	3512
2024 Q3	$561K	Buy	17,500 +8,826	+102%	+$330K	﹤0.01%	2247
2024 Q2	$327K	Buy	+8,674	New	+$365K	﹤0.01%	2292
2024 Q1	–	Sell	-7,804	Closed	-$285K	–	2973
2023 Q4	$285K	Buy	+7,804	New	+$204K	﹤0.01%	1830

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Verition Fund Management's SWTX Position: Q3 2025 in Review

Verition Fund Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 313,408 shares — an estimated $14.7M sold.

Verition Fund Management first reported a position in SWTX in Q4 2023 and held it in 5 quarters. The position peaked at $14.7M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Verition Fund Management reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Verition Fund Management sold 313,408 SpringWorks Therapeutics shares in Q3 2025, an estimated $14.7M.
Verition Fund Management first reported a position in SpringWorks Therapeutics in Q4 2023 and held it in 5 quarters.
Verition Fund Management's SpringWorks Therapeutics position peaked at $14.7M in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.